News & Updates

Once-daily oral treatment with the JAK inhibitor upadacitinib delivers clinically meaningful facial and total body repigmentation in adults and adolescents with non-segmental vitiligo, according to the phase III Viti-Up 1 and 2 trials.

Chronic kidney disease-associated pruritus (CKD-aP) is a debilitating condition that affects nearly half of patients undergoing dialysis, significantly impairing their quality of life (QoL), and requires multidisciplinary care, suggests a Singapore study.

Juvenile-onset mycosis fungoides (jMF) is usually diagnosed during its early stage and has an excellent prognosis, with overall survival (OS) of 99 percent at 5 years and 98 percent at 10 years, reveals a study.

In the treatment of patients with anti–PD-(L)1–resistant advanced melanoma, response with ceralasertib plus durvalumab is low, according to the phase II MONETTE study.

High-dose vitamin D shows promise in the treatment of toxic erythema of chemotherapy (TEC) and acute radiation dermatitis (ARD), according to a retrospective study.

A recent study has shown no significant differences in outcomes between initial topical and systemic corticosteroid therapy among patients with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.

The combination of fish oil supplementation and low-dose isotretinoin demonstrates noninferiority to isotretinoin monotherapy and keeps the skin hydrated in patients with moderate-to-severe acne vulgaris, reports a study. The combined treatment also helps control triglyceride levels.

Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.